user sign in

English

English
German
Italian
Spanish

My Therakos

Languages:

Therakos e-learning platform

Welcome to the Therakos Institute

TKS Institute TM CMYK 2022

At the Therakos Institute, our primary goal is to advance knowledge and understanding around Extracorporeal Photopheresis (ECP) immunomodulation. We have forged valuable partnerships with leading experts from around the world, regularly bringing our best and brightest together to provide accessible education to HCPs. Through these collaborations, we aim to build a better future for patients.

Gain online access to our live and on-demand webinars.

Sign-up to the upcoming webinars to learn more about the ECP therapy and get the opportunity to watch any past webinars you didn’t have chance to attend.

Register now

or

OUR EDUCATIONAL OFFER

Our Webinars Feature Image

Webinars

Up-to-date coverage of a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Explore our webinars

Symposia V2

Symposia

Major thought leaders present on specific topics on the latest in ECP Immunomodulation – guaranteed to be both stimulating and informative.

Centres Excellence V2

Centres of Excellence

We partner with several European Centres of Excellence (CoE) to provide high-quality professional education to committed healthcare professionals.

Centres of Excellence

Speaker Meetings V2

Speaker meetings

The latest scientific knowledge and advancements in ECP brought to life in conversation by major thought leaders.

Speaker Meetings

Rectangle 204 (1)

Ask the Expert

Private, one-to-one sessions with leading experts in their respective fields of relevance to ECP and its clinical applications.

Upcoming Events

CoE Course

Oct 30 - 31, 2023

A–Z of Treating Patients with ECP – The Nordic Approach (1)

The Oslo University Hospital, Oslo, Norway

Discover More

CoE Course

Nov 30 - Dec 1, 2023

THERAKOS CELLEX Photopheresis System Practical Course

The Tirol Kliniken, Innsbruck, Austria

Discover More

Speaker Meeting

Feb 9, 2024

8th Nordic Photopheresis Meeting

Helsinki, Finland

Rectangle 204 (1) (1)

Developing leadership in healthcare

An SDA Bocconi course.

Sponsored by Mallinckrodt.

Rectangle 204 (3)

Brilliant Speakers

Our communication course dedicated to bringing
our leaders into the new era of engagement.

Create your

Logomytherakos

account to access everything the Therakos Institute offers

Register now

or

Important Safety Information
For the Therakos^TM Photopheresis
Procedure

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.